FDA Clears MindMed IND for MM-120 in Treatment of Generalized Anxiety Disorder
MindMed’s LSD-based compound received FDA clearance, allowing the company to proceed with a trial that will be the first commercial study of LSD in over 40 years.
The study will assess 200 patients with generalized anxiety disorder to find the optimal dose of the formulation.
Shares of MNMD spiked 30% following the announcement 💰
